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Bladder cancer (BC) is the ninth most common cancer worldwide, but molecular
changes are still under study. During tumor progression, Epithelial cadherin (E-cadherin)
expression is altered and β-catenin may be translocated to the nucleus, where it
acts as co-transcription factor of tumor invasion associated genes. This investigation
further characterizes E-cadherin and β-catenin associated changes in BC, by combining
bioinformatics, an experimental murine cell model (MB49/MB49-I) and human BC
samples. In in silico studies, a DisGeNET (gene-disease associations database)
analysis identified CDH1 (E-cadherin gene) as one with highest score among 130
BC related-genes. COSMIC mutation analysis revealed CDH1 low mutations rates.
Compared to MB49 control BC cells, MB49-I invasive cells showed decreased
E-cadherin expression, E- to P-cadherin switch, higher β-catenin nuclear signal and
lower cytoplasmic p-Ser33-β-catenin signal, higher Ephrin-B1 ligand and EphB2
receptor expression, higher Phospho-Stat3 and Urokinase-type Plasminogen Activator
(UPA), and UPA receptor expression. MB49-I cells transfected with Ephrin-B1 siRNA
showed lower migratory and invasive capacity than control cells (scramble siRNA).
By immunohistochemistry, orthotopic MB49-I tumors had lower E-cadherin, increased
nuclear β-catenin, lower pSer33-β-catenin cytoplasmic signal, and higher Ephrin-B1
expression than MB49 tumors. Similar changes were found in human BC tumors, and
83% of infiltrating tumors depicted a high Ephrin-B1 stain. An association between higher
Ephrin-B1 expression and higher stage and tumor grade was found. No association was
found between abnormal E-cadherin signal, Ephrin-B1 expression or clinical-pathological
parameter. This study thoroughly analyzed E-cadherin and associated changes in BC,
and reports Ephrin-B1 as a new marker of tumor aggressiveness.
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INTRODUCTION
Bladder cancer (BC) is one of the ten solid tumors with
highest incidence and mortality worldwide, with 549,393
new cases and 199,922 deaths reported in 2018, and
with an increase of 50% expected for 2040 (International
Agency for Research on Cancer; WHO1). Clinically, it is
classified as non-muscle-invasive (NMIBC) and muscle-
invasive (MIBC) or infiltrating BC, being the latter highly
aggressive. Urothelial tumors represent >90% of the cases;
while 75% are limited to the mucosa or submucosa at the
time of diagnosis, 10–30% NMIBC patients progress to
MIBC and 50–70% have tumor recurrence (1). Thus, muscle
invasion is a key event in BC, being important to identify
MIBC biomarkers for accurate treatment and understanding
the underlying mechanisms to prevent tumor progression
and aggressiveness.
Among molecular changes associated to BC, a decreased
expression of epithelial cadherin (E-cadherin) has long been
reported (2). In a systematic review and meta-analysis, reduced
E-cadherin was associated with poor BC prognosis (3); however,
the underlying mechanisms have not been fully characterized.
E-cadherin is the founder member of the cadherin superfamily
(4). It is a 120 kDa transmembrane glycoprotein encoded
by the CDH1 gene; its extracellular domain mediates cell-cell
adhesion, while the cytoplasmic domain binds to β-catenin that
links E-cadherin to the actin cytoskeleton, and is involved in
signal transduction (5). E-cadherin decrease/loss expression is
a hallmark of Epithelial-to-Mesenchymal Transition (EMT) that
promotes cell motility/invasive behavior, cancer progression and
metastasis (6, 7). Alterations in E-cadherin expression during
EMT are accompanied by increased expression of transcriptional
represors, β-catenin loss at the cell membrane, and filamentous
actin (F-actin) belt replacement by a network of stress fibers.
Also, it is tipically characterized by an increased expression
of neural (N-cadherin) and, in some cases, by placental (P-
cadherin) cadherin, a phenomenon called cadherin switch.
Some evidence of EMT-related events has been reported in
BC (8–10).
This report further characterizes alterations in E-
cadherin expression and EMT-related events in BC with
the aim to identify novel markers of BC progression.
Studies were addressed in the MB49 and MB49-I murine
model of tumor progression (11, 12), and in BC patient
tissue samples.
MATERIALS
Chemicals were of analytical and tissue culture grade and
purchased from BioRad (Richmond, CA, USA), Thermo-
Fisher Scientific (Carlsbad, CA, USA), and Sigma Chemical
Co. (St. Louis, MO, USA), unless specifically indicated.
Primary antibodies used were: Anti-E-cadherin: (1) 610181 (BD
1International Agency for Research on Cancer;World Health Organization. http://
globocan.iarc.fr.
Biosciences, San Diego, CA, USA), (2) HECD-1 (Thermo); Anti-
β-catenin (610153; BD); Anti-phospho-Ser33-β-catenin (pSer33-
β-catenin; Ser33-R; SCB); Anti-N-cadherin (H-63, SCB); Anti-
P-cadherin (H-105, SCB); Anti-Ephrin-B1 (A-20, SCB); Anti-
EphB2 (H-80, SCB); Anti-Signal transducer and activator
of transcription 3 (STAT3) (B-7, SCB); Anti-phospho-STAT3
(pSTAT3) (C-20, SCB); Anti-Proliferating cell nuclear antigen
(PCNA) (PC10, SCB), Anti-actin (I-19, SCB); Anti-β-tubulin
(D-66, Sigma). Secondary antibodies used were Cy3-labeled
anti-mouse or anti-rabbit (Sigma) and FITC-labeled anti-
mouse (Vector Lab. Inc., Burlingame, CA, USA) IgGs for
fluorescence immunocytochemistry, Anti-mouse (Vector) or
Anti-rabbit (Sigma) IgGs coupled to horseradish peroxidase
for Western immunoblotting. In control experiments, primary
antibodies were replaced by purified mouse or rabbit IgGs,
as required.
Murine Cell Lines and Tumors
Established MB49 and MB49-I mouse cell lines were used
as experimental models. The MB49 cell line was generated
from an in vitro neoplastic transformation of mouse bladder
epithelium primary cultures (13). The MB49-I cell line was
originated after in vivo successive passages of a primary tumor
obtained by subcutaneous inoculation of MB49 cells in C57Bl/6J
males (11).
Murine bladder tumors were generated by orthotopic
inoculation of MB49 and MB49-I cells into C57BL/6 mice
bladder (11). Mice were handled in accordance with the
international procedure for Care and Use of Laboratory Animals;
a protocol was approved by the Institute of Oncology Angel H.
Roffo Review Board (#2012/02).
Human Tumor Samples
Human BC tissue samples were obtained from patients diagnosed
with urothelial BC at Hospital Italiano of Buenos Aires,
between 2012 and 2016. The project was approved by Ethics
Committees of Hospital Italiano and IBYME (Protocol #C004-
1/2012); patients signed a written informed consent. Ten fresh
biopsies (non-tumor and tumor sections, 1 cm3 each) from
patients diagnosed with infiltrating BC were collected from the
surgical piece, placed in RNA Later R© and subjected to RNA
extraction and subsequent quantitative real-time PCR analysis.
In addition, 38 paraffin-embedded tissue samples from patients
diagnosed with BC and subjected to transurethral resection or
radical cystectomy, were included in the study and analyzed
by immunohistochemistry; Supplementary Table 1 summarizes
available information on patient gender, age, tumor stage and
grade, as well as evidence of metastasis.
PCR Primers
Primers were designed for endpoint (analytical) and quantitative
real time PCR protocols using Primer-BLAST tool (http://www.
ncbi.nlm.nih.gov/tools/primer-blast); sequences and expected
PCR fragment sizes are listed in Supplementary Table 2. Some
primers were previously reported (14, 15).
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METHODS
Bioinformatics
To perform text mining on BC gene-disease associations, the
DisGeNET discovery platform (http://www.disgenet.org/) was
used. DisGeNET integrates information on human diseases
and their genes from expert-curated databases and scientific
literature found by means of text-mining approaches (16). Gene-
disease associations are ranked according to DisGeNET score,
and annotated with DisGeNET gene-disease association type
ontology. A set of search terms related to BC was selected to
browse all DisGeNET databases and to search for CDH1 among
the output list. The DisGeNET version containing 628,685
associations between 17,549 genes and 24,166 diseases was used
in the present study (March, 2019).
Listed somatic mutations in the CDH1 (E-cadherin) and
CTNNB1 (β-catenin) genes in BC were retrieved from the
COSMIC (http://cancer.sanger.ac.uk/cosmic) catalog of public
domain data tool. COSMIC provides information about
mutations affecting tumor-associated genes, and establishes a
hierarchy of the 20 most commonly mutated genes in a specific
tumor, as well as number of cases in which a mutation was
reported. For each mutation, information is available on position
and type of change, as well as amino acid(s) involved; in case
of substitutions, it provides information on the specific change
that occurs with the mutation. The COSMIC v88 used in this
study includes over 6 million coding mutations across than >1.4
million tumor samples curated from >26,000 publications (17).
Information was filtered to obtain data from samples of patients
diagnosed with transitional cell carcinoma of the bladder, which
were 5,774 of the total 8,359 BC samples (March, 2019).
MB49 and MB49-I Cell Culture and
Orthotopic Tumors
MB49 and MB49-I cell lines were cultured as previously
reported (11). At 70–80% confluence, cells were
harvested and processed for RNA and protein (Western
immunoblotting/immunocytochemistry) analyses.
MB49 and MB49-I orthotopic tumors were generated as
previously described (11). Basically, orthotopic cell injection
in C57BL/6 female mice was performed by placing a catheter
into the urethra. Previously, focal electrocautery was performed
to induce punctual damage to the bladder wall. MB49 and
MB49-I suspensions from subconfluent cell culture monolayers
were instilled in 100 µl RPMI 1640 medium. Mice were
monitored twice weekly for hematuria and by bladder palpation.
Two weeks after tumor cell inoculation, the animals were
sacrificed and tumors included in paraffin for subsequent
immunohistochemical analysis.
Transient Transfection Assays
MB49-I cells transient transfection was performed using
Lipofectamine R© 2000 (Thermo) and 100 pmol/ml of a specific
small interfering Ephrin-B1 RNA (siRNA) (#39437, SCB; pool of
3 target-specific 19–25 nt siRNAs designed to knock down gene
expression) following a standard procedure (18). Control assays
with scramble siRNA (#37007, SCB) were included.
RNA Extraction, cDNA Synthesis,
Standard, and Quantitative Real Time PCR
Cell and tissue total RNA was isolated and processed for
complementary DNA (cDNA) synthesis (14, 15, 18). PCR
samples were prepared with SYBR Green R© PCR Master Mix
(Thermo) mixture and run in CFX96 TouchTM (BioRad) PCR
unit. Triplicate samples and negative controls (no template)
were always included. Dissociation curves were run to confirm
signal specificity. GAPDH was selected as endogenous control
and MB49 cells as reference. The calculation describing these
relations is 2−11Ct, where 11Ct = [1Ct test sample – 1Ct
reference sample], and 1Ct = [Ct gene under study – Ct
endogenous gene]. Alternatively, calculations were done using
2−1Ct method, where 1Ct = [Ct gene under study – Ct
endogenous gene]. Primer sequences and expected PCR fragment
sizes are listed in Supplementary Table 2.
Protein Extraction and Western
Immunoblotting Protocols
Protein extraction and analysis was done essentially as previously
described (14, 15, 18). Basically, cell monolayers were incubated
with PBS on ice, followed by protein extraction with RIPA
(20mM Tris-HCl, pH = 7.5, 150mM NaCl, 1% NP-40, 1%
sodium deoxycholate, and standard protease inhibitors cocktail)
buffer. For Stat3 and phospho-Stat3 detection, buffer was
supplemented with 1mM orthovanadate, 10mM β-glycerol
phosphate, and 25mM sodium fluoride (phosphatase inhibitors).
Cells were harvested using a scrapper, and lysis was completed
by physical rupture with a 22G needle syringe. Cell lysates
were centrifuged at 13,000 × g for 30min, pellets were
discarded, and protein content was quantified using the
Bradford method with a commercial reagent (BioRad) following
manufacturer’s instructions.
The NE-PER Nuclear and Cytoplasmic Extraction Reagents
(Pierce Protein Research Products (Thermo) commercial kit
was used to obtain MB49 and MB49-I cell cytoplasmic and
nuclear extracts.
Proteins were separated by electrophoresis in 10% Sodium
Dodecyl Sulfate-PolyAcrylamide Gel Electrophoresis (SDS-
PAGE) followed by Western immunoblotting. Proteins were
immunodetected using standardized protocols and specific
antibodies. Protein bands obtained in development plates
(AGFA, Belgium) were digitized using a scanner (Hewlett-
Packard, USA) and, in some cases, the signal density was
quantified with the Image J software (Wright Cell Imaging




Cells grown on glass coverslips were fixed and subjected to
immunocytochemical analysis (14, 15, 18). Cell nuclei were
stained with 1µg/ml Hoechst 33342 or 5µg/ml propidium
iodide (BD Pharmigen) in PBS for 5min, as specifically indicated.
Negative controls were done placing purified mouse or rabbit
IgG at the same concentration of primary antibody. Presence
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of filamentous actin (F-actin) was detected with AlexaFluor
488 phalloidin (Thermo). Stained cells were observed in
a fluorescence microscope (Nikon-C2, excitation filters 488
nm/544 nm, emission filters 523–530 nm/570-lp nm); when
required, images were analyzed using the Image J software.
Immunohistochemical Analysis
Immunohistochemical analysis was performed in paraffin-
embedded sections from orthotopic tumors of MB49 and
MB49-I cell lines, normal C57BL/6 mice bladder and human
bladder tumors. Five µm-tissue sections were stained with
hematoxylin/eosin for cell morphology analysis or subjected
to immunohistochemistry of E-cadherin, β-catenin, pSer33-β-
catenin, and Ephrin-B1. In negative controls, primary antibody
was replaced by IgG added at the same concentration of
primary antibodies. Signal was developed with LSAB+System-
HRP (Dako) colorimetric system. Ephrin-B1 staining was scored
by two anatomo-pathologists, according to the percentage of
stained cells (0, no stained cells, 1, 1 to 29%, 2, 30 to 69%,
3, 70 100% stained cells) and the intensity of the signal (0,
without staining; 1: weak; 2: moderate; 3: strong), and a total
score was calculated (≥3, “high” Ephrin-B1; <3 “low” Ephrin-
B1). E-cadherin staining score was normal (≥1–29% cells with a
membrane signal) or abnormal (low or high signal, but without
membrane localization).
Cell Migration and Invasion Assays
Cell migration and invasion assays were run in MB49-I cells
transiently transfected with a siRNA toward Ephrin-B1 and
Control (scramble SiRNA). The procedure was done basically
as previously reported (18) (8 h to assess migration and 40 h to
evaluate invasion). In the lower part of the device, medium with
10% FBS was placed to act as chemoattractant. Cells were fixed
and stained with 0.5% violet crystal solution in 20% methanol.
Images from six different fields were recorded and cells counted
using the Image J software.
Statistical Analysis
All experiments were run in triplicates. Results are expressed as
mean± SEM. Statistical analysis was done using GraphPad Prism
software, version 5.01 (GraphPad Software, USA) and InfoStat,
version 2015 (InfoStat Group, Argentina). For assays involving
two groups, the Mann Whitney or Wilcoxon test was performed,
as required; for assays involving >2 groups, the Kruskal
Wallis test followed by multiple decompositions according
to Dunn was run. Analysis of Ephrin-B1 and E-cadherin
immunohistochemistry results was done using the Pearson Chi-
Square test. A P < 0.05 was considered statistically significant.
RESULTS AND DISCUSSION
Bioinformatics Survey of BC and
E-Cadherin
A bioinformatics analysis was done to retrieve a list of BC-
associated genes. To perform this analysis, the DisGeNET
database was surveyed to identify genes annotated to the terms
“Malignant neoplasm of urinary bladder,” “Bladder Neoplasm,”
“Transitional cell carcinoma of bladder,” “Carcinoma in situ of
bladder,” and “Carcinoma of bladder.” One hundred and thirty
genes were identified; CDH1 was among genes with highest
score (CDH1, CDKN2A, ERCC2, FGFR3, GSTP1, HRAS, NQO1,
TP53, TSC1), specifically when only the term “Bladder neoplasm”
was surveyed. Figure 1 shows a graphical representation of both
networks, and Supplementary Table 3 lists genes retrieved from
DisGeNet survey, with their association type and score.
In addition, a search of CDH1 somatic mutations in BC was
done using the COSMIC bioinformatics tool. As a result, CDH1
mutations were found in 17/587 (2.90%) tested BC samples, 15
of which were located in exonic sequences of different protein
segments [residues 9, 27, 28, 150, 159, 210, 240, 248, 357, 638
(twice), 641, 677, 731, 785]. Table 1 lists the identified mutations.
Altogether, these studies showed evidence of CDH1/E-
cadherin involvement in BC, which was related only in few
cases to mutations in the CDH1 gene. Results of these surveys
encouraged authors to further investigate changes in E-cadherin
and related molecules, and the underlying mechanisms in BC.
Expression of E-Cadherin and
EMT-Related Markers in MB49 and MB49-I
Murine BC Cell Lines
Initial studies were focused on evaluating the expression of E-
cadherin and some EMT-related genes in MB49 and MB49-I in
vitro cell cultures (Figure 2A). While in standard RT-PCR assays
E-cadherin mRNA was detected in both cell lines, quantitative
real-time PCR analyses revealed a 30% decrease (P < 0.05) in
E-cadherin transcript levels in MB49-I cells compared to MB49
parental cells (Figure 2B). In agreement with these findings, E-
cadherin protein analysis by Western immunoblotting revealed
significant lower expression levels of the 120 KDa full-length
adhesion full-length protein form in MB49-I cells, representing
<10% of those found in MB49 cells (Figures 2C,D). These
findings are consistent with early studies done in human samples,
in which lower E-cadherin levels were found in infiltrating than
in superficial bladder tumors (2, 19, 20). In any case, while
a 30% decrease in the CDH1 transcript was found in MB49-I
compared toMB49 cells, a sharp decrease to undetectable protein
levels was determined. Differences observed between both cell
lines in E-cadherin transcript and protein levels may relate to
expression levels of the adhesion protein present in these cell
lines and methodologies used to detect them. Both cell lines
depict low E-cadherin mRNA expression levels (around Ct 36),
but the quantitative real time PCR procedure can accurately
measure low transcript levels in both cell lines. On the other
hand, expression levels of the adhesion protein may be close
to the limit of detection, resulting in a very poor/absent signal
in MB49-I cells, even when using sensitive detection systems.
Alternatively, differences between RNA and protein levels in
the murine cell lines may result from selective regulatory post-
transcriptional, translational and post-translational mechanisms,
i.e., pre-mRNA splicing, polyadenylation, capping, and mRNA
transport, turnover, storage, and translation (21). Some post-
transcriptional mechanisms have been shown to critically
influence EMT (22–24). Among mechanisms determining
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FIGURE 1 | E-cadherin and Bladder Cancer. A bioinformatics survey. (A) Network representation of genes annotated to the terms “Malignant neoplasm of urinary
bladder,” “Bladder Neoplasm,” “Transitional cell carcinoma of bladder,” “Carcinoma in situ of bladder,” and “Carcinoma of bladder” obtained with DisGeNET using
Cytoscape. A yellow node represents the “Bladder Cancer” disease node. Green nodes represent disease-related genes (130 genes). In red, the CDH1 gene is
highlighted. (B) Network representation of genes annotated to the term “Bladder Neoplasm” obtained with DisGeNET using Cytoscape. A yellow node represents the
Bladder Cancer disease node. Other nodes represent disease-related genes, showing same colors for equal score. Red colored nodes depict the highest score (0.6);
the CDH1 gene is among these genes and highlighted with a different node shape. Information on the score and association type is presented in
Supplementary Table 3.
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TABLE 1 | CDH1 somatic mutations and BC.
Transcript Sample ID AA mutation CDS mutation
ENST00000261769 2727096 p.S9* c.26C > A
ENST00000261769 2726284 p.P27fs*27 c.79_85delCCCTGCC
ENST00000261769 2725343 p.C28fs*1 c.84_85delCC
ENST00000261769 2721157 p.R150K c.449G > A
ENST00000261769 2720314 p.P159 > HT c.475_476insATA
ENST00000261769 2714567 p.E210Q c.628G > C
ENST00000261769 2721980 p.I248N c.743T > A
ENST00000261769 2719872 p.? c.1320 + 2T > G
ENST00000261769 2772700 p.? c.1320 + 5G > A
ENST00000261769 2719775 p.K557N c.1671G > C
ENST00000261769 2724773 p.W638* c.1914G > A
ENST00000261769 2097275 p.W638* c.1914G > A
ENST00000261769 2722509 p.Q677* c.2029C > T
ENST00000261769 2097330 p.L731F c.2191C > T
ENST00000261769 992969 p.N785N c.2355C > T
ENST00000261769 1995691 p.N240Xfs*10 c.?
ENST00000261769 2395174 p.Q641* c.?
A bioinformatics analysis using COSMIC. Data retrieved from the COSMIC database
(GRCh38 · COSMIC v90).
mRNA turnover by ribonucleoproteins, HuR is one of the
best-studied regulators of cytoplasmic mRNA fate (21), and
evidence supports its interaction with the 3’-untranslated region
of E-cadherin mRNA and regulation of E-cadherin translation
(25). In BC, HuR appears to regulate the expression of many
urinary tumors-associated molecules (26), and a significant
association between positive cytoplasmic HuR signal and high
tumor grade, pT stage andmicro-vessel density has been reported
in BC (27). Differences found between E-cadherin expression
levels in both cell lines and between mRNA and protein levels
found may be, at least in part, related to the expression of
HuR in the murine cell model and modulation of E-cadherin
mRNA and protein stability. Mouse cells have been reported
to conserve consensus sequences and mechanisms found in
humans for these regulations (28). In addition to this regulatory
mechanism, the translated E-cadherin protein may be subjected
to proteolytic cleavage, catalyzed by matrix metalloproteinases
(MMP-3, MMP-7, MMP-9, and MT1-MMP), A-disintegrin-
and-metalloproteinases (ADAM10 and ADAM15), plasmin, and
kallikrein 7, releasing the 86 KDa ectodomain fragment and a 38
KDa fragment associated to the membrane, which is degraded
to smaller fragments (5, 29). Since MMP9 has been previously
reported in BC (30) and in the MB49-I cell model (11), part
of the lower signal may be the result of E-cadherin processing;
E-cadherin cellular fragments may not be resolved in 10% SDS-
PAGE gels, are below the limit of the detection, or lack the
antibody epitope, and are not shown in the profile.
Since transcriptional repression is one mechanism associated
to decreased E-cadherin (5), expression of Snail, Slug, Zeb1, and
Twist transcriptional repressors was analyzed in both cell lines.
As shown in Figure 2E, an increased expression (P < 0.05) of
Snail and Slug transcripts was observed inMB49-I cells compared
toMB49 cells. On the other hand, while lower levels (P < 0.05) of
Zeb1 mRNA were detected in MB49-I cells compared to those in
MB49 cells, no detectable levels of Twist were found in either BC
cell line. Findings in the present report are in line with a previous
study by Gou et al. (31), describing a relationship between a
higher Snail expression, and the presence of advanced tumors
among 332 human samples from patients with superficial BC
evaluated by immunohistochemistry; in the same report, Snail
was a predictor of disease recurrence and progression. Moreover,
a higher expression of Slug was also previously reported in
infiltrating tumors, in a study of 47 patients diagnosed with
BC (32). Finally, Tang et al. (33) reported significantly lower
expression levels of Twist1 mRNA in 13 paired urothelial bladder
cancer specimens than the non-tumor mucosas.
The cadherin switching phenomenon represents an important
aspect of the EMT, and it has been typically described as
a process by which E-cadherin expression is replaced by N-
cadherin expression (34, 35). However, later studies found an
abnormal expression of other members of the superfamily as
part of the cadherin switch (36). Thus, the E-cadherin to N-
cadherin and/or P-cadherin switch phenomenon was analyzed
in the in vitro murine BC model. Regarding N-cadherin,
mRNA expression analysis revealed significant lower levels of
this transcript in MB49-I compared to MB49 cells (Figure 2F).
In line with these findings, fluorescence immunocytochemistry
revealed a lower signal for N-cadherin in MB49-I compared to
MB49 cells (Figure 2G). Previous studies have reported ∼40%
of bladder tumors depicting a positive signal for this protein
(37–39). This percentage was found in either NMIBC (37)
or MIBC (40) tumor cohorts, showing that not all invasive
tumors show increased expression of N-cadherin. While some
of these studies showed an association between increased N-
cadherin expression and recurrence-free survival (37, 38), others
failed to find a relationship between N-cadherin expression with
clinicopathological parameters (39, 41). In line with the results
of the present report, a study by Jäger et al. (42) found a positive
N-cadherin expression in superficial (Ta/T1) cases to be a risk
factor, and a lack of expression in MIBC cases correlated with
reduced patient survival. Moreover, they reported 14% (13/92)
N-cadherin-negative (2 × T2, 8 × T3, and 3 × T4) MIBC,
and 12/13 patients died of BC within 18 months; the average
survival time in this group was 3.5-fold lower than in MIBC
cases expressing N-cadherin. In another study, the N-cadherin-
negative muscle-invasive tissue samples (“high risk”) depicted a
2-fold higher expression level of the VEGF angiogenic factor than
N-cadherin-positive muscle invasive cancers (43), highlighting
the association between negative N-cadherin expression in BC
and tumor aggressiveness.
With regard to P-cadherin assessment, transcript (Figure 2H)
and protein (Figure 2I) levels were higher (P < 0.05) in MB49-I
cells compared to MB49 cells. Results from this report agree with
several studies that show P-cadherin expression in association
with BC progression. Rieger-Christ et al. (44) described P-
cadherin in over 90% of the cases in a cohort of ∼100 tumors;
authors also reported N-cadherin expression, absent in normal
urothelium but localized to the membrane in focal areas of the
tumor mass in invasive tumors. Later, Bryan et al. (45) studied
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FIGURE 2 | EMT molecules and BC. Studies in the MB49 and MB49-I cell murine models. (A) Phase contrast microscopy of MB49 and MB49-I cells. Graph Bar =
20µm. (B) Quantitative analysis of E-cadherin mRNA in MB49 and MB49-I cells by real-time PCR. Results are plotted as mean relative expression with Standard Error
(Continued)
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FIGURE 2 | of the Mean (SEM); *P < 0.05. (C) Immunodetection of E-cadherin protein forms in total protein extracts of MB49 and MB49-I cells after performing 10%
polyacrylamide gel electrophoresis (SDS-PAGE) followed by Western immunoblotting with anti E-cadherin antibody (610181; 2.5µg/ml). Actin (I-19; 2µg/ml) was
used as loading control. References indicate the molecular weight standards of 66 and 31 KDa and the 120 KDa E-cadherin full length form. (D) Densitometric
analysis of results obtained by Western Immunoblotting for the expression of E-cadherin performed with the ImageJ program; results are shown as percentage of the
expression level of CadE in line MB49-I. Assessments of 3 replicates were included in the analysis. Data is shown as mean ± SEM. (E) Quantitative analysis by
real-time PCR of Snail, Slug, Zeb1, and Twist mRNA expression in MB49 and MB49-I cells. For Twist, mouse testis was used as a positive control. ns, not significant;
*P < 0.05. (F) Quantitative analysis by real-time PCR of N-cadherin mRNA expression in MB49 and MB49-I cells. (G) Fluorescence immunocytochemistry analysis by
confocal laser microscopy of N-cadherin (H-63; 2µg/ml) in MB49 and MB49-I cells. Negative controls are shown on the right, and cell nucleae were visualized using
HOESCHT 33342. (H) Quantitative analysis by real-time PCR of P-cadherin mRNA expression in MB49 and MB49-I cells, *P < 0.05. In all cases, relative expression
levels of each mRNA was calculated using actin as endogenous gene and the MB49 cell line as reference. (I) Fluorescence immunocytochemistry analysis by confocal
laser microscopy of P-cadherin (H-105; 2µg/ml) in MB49 and MB49-I cells. Negative controls are shown on the right, and cell nucleae were visualized using
HOESCHT 33342.
over 150 bladder tumors, finding increased membranous P-
cadherin expression in almost half of all MIBC, accompanied
by significantly lower expression of E-cadherin. Increased P-
cadherin expression was associated with worse BC-specific
survival, and P-cadherin status was an independent prognostic
factor (alongside grade and stage). Moreover, functional in vitro
experiments showed that altering the balance of E- and P-
cadherin in favor of P-cadherin expression enhanced anchorage-
independent growth, and P-cadherin alone was unable tomediate
normal cell–cell adhesion. Authors concluded that P-cadherin
expression promoted a more malignant and invasive phenotype
of BC, even in the presence of E-cadherin. The same year
Mandeville et al. (46) reported the expression of P-cadherin
in BC, and found that P-cadherin overexpression induced an
increase in migratory capacity in in vitromodels. VanMarck et al.
(47) later showed that stable knockdown of P-cadherin in RT-
112 BC cells diminished invasion and migration, and promoted
intercellular adhesion, supporting a P-cadherin transformation
promoting role in BC.Mandeville et al. (46) suggested P-cadherin
to have a role in regulating migration of basal cells to the
intermediate cell layer in normal urothelium as well as a role
in neoplastic progression, while Bryan et al. (45) suggested that
P-cadherin may be induced in BC to reduce cell-cell adhesion
and to enable cell-matrix interactions as a first step to invasion
in a similar fashion to N-cadherin. In Jäger’s report (42), high P-
cadherin gene expression proved to be an independent favorable
prognostic factor of cancer-related survival, and a risk factor of
recurrence in superficial cancers after tumor resection. In 2014,
Wang et al. (48) reported a correlation between P-cadherin high
expression and tumor progression. Finally, using a molecular
approach, a thorough report by Choi and collaborators described
the identification of distinct basal and luminal subtypes of MIBC
with different sensitivities to frontline; in the study, CDH3,
the gene encoding P-cadherin was listed among gene classifiers
for muscle invasive progression and muscle invasive overall
survival (49).
Protein Assessment of the Adherent
Complex Members. β-Catenin Expression
Analysis
Considering the relevance of the adhesion complex integrity
upon cell-cell adhesiveness, and the decreased E-cadherin mRNA
and protein levels found in MB49-I cells, subcellular localization
of some members of the adherent complex was evaluated.
Localization of E-cadherin and β-catenin was determined
in both cell lines by fluorescence immunocytochemistry,
while evaluation of the actin cytoskeleton organization was
performed by Filamentous actin (F-actin) staining with
Alexa488-phalloidin. As shown in Figure 3A (top panels),
immunolocalization analysis of E-cadherin in whole cells
revealed a signal in the cytoplasm of both cell lines, but ∼50%
less intense in MB49-I cells, in line with the results of mRNA
and total E-cadherin protein expression analysis described above
(Figure 2C). On the other hand, β-catenin immunolocalization
analysis revealed striking differences between both cell lines;
while in MB49 cells the β-catenin signal was localized mainly in
the cytoplasm, in MB49-I cells it was stronger and distributed
in the cytoplasm and nucleus (Figure 3A, middle panel). F-actin
fluorescence distribution evidenced stress fibers in both lines
(Figure 3A, bottom panels).
To confirm a higher expression of β-catenin protein in
MB49-I cells, Western immunoblotting of total protein extracts
from both cell lines was done. In agreement with the
immunocytochemistry results, higher levels of β-catenin were
detected inMB49-I cells compared toMB49 cells (Figures 3B,C).
These changes could not be attributed to an increase in mRNA
expression (MB49: 1; MB49-I: 0.978±0.043; ns). Based on
these findings, β-catenin subcellular distribution was quantified,
finding nuclear localization in ∼80% of MB49-I cells and in
∼10% of MB49 cells (Figure 3D). This evaluation was also
done in cytoplasmic and nuclear protein extracts (β-tubulin
cytoplasmic marker; PCNA nuclear marker). As shown in
Figure 3E, β-catenin signal in MB49-I cells was weaker in the
cytoplasmic fraction and stronger in the nuclear fraction, when
compared to MB49 cells.
In normal cells, β-catenin localizes at the cell membrane in a
complex with E-cadherin; cytoplasmic β-catenin is maintained at
low levels, being constitutively captured by a destruction complex
that facilitates its N-term phospho targeting, ubiquitination and
destruction in the proteasome. The adenomatous polyposis coli
(APC) and Axin are structural components of the destruction
complex, while CK1 casein kinases and 3 glycogen synthase
kinase-3β (GSK-3β) are recruited to serine phosphorylate β-
catenin. Under certain conditions, β-catenin accumulates in the
cytosol and is shuttled to the nucleus, where it binds and forms
complexes with transcription factors of the lymphoid enhancer
factor (Lef)/T-cell factor (TCF) family, and activates target
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FIGURE 3 | Evaluation of adherent complex members in MB49 and MB49-I cells. (A) Fluorescence immunocytochemistry of E-cadherin (610181; 2.5µg/ml), (top
panels) and β-catenin (610153; 2.5µg/ml) (middle panels) and analysis by confocal microscopy. Bar indicates 20µm (Magnification 40×). Negative controls are
shown on the right; cell nucleae were visualized using HOESCHT 33342. Confocal laser microscopy analysis of actin cytoskeleton organization by visualization of
filamentous actin (F-actin) labeled with phalloidin-Alexa488 in MB49 and MB49-I cells (bottom panels). (B) Immunodetection of β-catenin (610153; 2.5µg/ml) and
pSer33-β-catenin (Ser33-R; 4µg/ml) after performing 10% SDS-PAGE followed by Western immunoblotting of MB49 and MB49-I cell extracts. Loading controls were
done using a specific antibody toward β-tubulin (D-66; 0.05µg/ml). (C) Densitometric quantification analysis of β-catenin in MB49 and MB49-I cells using the Image J
software; *P < 0.05. (D) Fluorescence immunocytochemistry of β-catenin (610153; 2.5µg/ml) and analysis by confocal microscopy in MB49 and MB49-I cells. Cell
nuclei were visualized using Propidium Iodide. Bar = 20µm (Magnification 40×). MB49-I cells with nuclear localization of β-catenin are indicated with an arrow.
Graphic representation of the percentage of MB49 and MB49-I cells with β-catenin signal in the nucleus; *P < 0.05. (E) Detection of β-catenin (610153; 2.5µg/ml)
after 10% SDS-PAGE followed by Western immunoblotting of cytoplasmic and nuclear fractions of MB49 and MB49-I cell extracts. Cell fraction loading and purity:
β-tubulin (positive in the cytoplasmic fraction; D-66, 0.05µg/ml), PCNA (positive in the nuclear fraction; PC10, 0.2µg/ml). (F) Fluorescence immunocytochemistry and
confocal laser microscopy analysis in MB49 and MB49-I cells of pSer33-β-catenin (Ser33-R; 4µg/ml). Negative controls shown on the right; cell nucleus visualized
using HOESCHT 33342.
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FIGURE 4 | Expression analysis of Ephrin-B1 and related proteins in the MB49 and MB49-I cell murine models. (A) Quantitative expression analysis of Ephrin-B1
mRNA in MB49 and MB49-I cells by real-time PCR. (B, Left) Immunodetection of Ephrin-B1 (A-20; 2µg/ml) after 10% SDS-PAGE of MB49 and MB49-I cells protein
(Continued)
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FIGURE 4 | extracts followed by Western Immunoblotting. β-tubulin (D-66, 0.05µg/ml) used as loading control. (Right) Densitometric analysis of Ephrin-B1
immunodetection; *P < 0.05. (C) Fluorescence immunocytochemistry and analysis by confocal laser microscopy of Ephrin-B1 (A-20; 2µg/ml) in MB49 and MB49-I
cells. (Right) Negative controls; cell nucleae were visualized using HOESCHT 33342. (D) Quantitative analysis of Ephrin-B1 mRNA by real-time PCR in cells transiently
transfected with an Ephrin-B1specific siRNA (cells MB49-I siRNA Ephrin-B1) or control siRNA (MB49-I siRNA Control cells); *P < 0.05. (E, Left) Representative images
of the migration assay obtained by phase contrast microscopy (Magnification 20×). (Right) Graphical representation of the migration assay results in siRNA MB49-I
Ephrin-B1 and siRNA control MB49-I cells. The average number of cells in each of the evaluated fields is plotted; *P < 0.05. (F, Left). Representative images of the
invasion assay obtained by phase contrast microscopy (Magnification 20×). (Right) Graphic representation of the invasion assay results. The average number of cells
in each of the evaluated fields is plotted; **P < 0.001. (G, Left) Immunodetection of EphB2 (H-80; 2µg/ml) in MB49 and MB49-I cells protein extracts after 10%
SDS-PAGE/Western Immunoblotting. Immunodetection of β-tubulin was carried out as loading control. (Right) Densitometric analysis of EphB2; *P < 0.05. (H, Left)
Immunodetection of pStat3 (C-20; 2µg/ml) and Stat3 (B-7; 2µg/ml) of protein extracts of MB49 and MB49-I cells, after 10% SDS-PAGE/Western Immunoblotting.
Loading control: β-tubulin (D-66, 0.05µg/ml). (Right) Densitometric analysis of phospho-Stat3 immunodetection. Signal intensity of this molecule was normalized using
Stat3 signal intensity and MB49 cells as reference; *P < 0.05. (I) Quantitative analysis of uPA and uPAR mRNA by real-time PCR in MB49 and MB49-I cells; *P < 0.05.
genes, which are regulators of cell proliferation and involved in
tumorigenesis. N-terminal β-catenin phosphorylation is required
for its degradation and for attenuating its effect on transcription
(50–52). β-catenin nuclear localization has been related to tumor
progression and aggressiveness in several tissues (i.e., breast,
renal, and colorectal cancer); in particular, there are reports
describing an aberrant localization of β-catenin in the cell
cytoplasm and nucleus in BC (53, 54).
Taking into account that β-catenin is phosphorylated in the
degradation complex by GSK-3β in Ser33, Ser37, and Ser41
(52, 55), presence and localization of pSer33-β-catenin were
assessed in MB49 cells and MB49-I cells, both by Western
immunoblotting and fluorescent immunocytochemistry using
a commercial antibody. As result, lower levels of P-Ser33-
β-catenin were found in MB49-I cells compared to MB49
cells (Figures 3B,F, respectively), in agreement with β-catenin
localization found in the MB49-I cell nucleus. In line with these
findings, Roy et al. (56) reported the results of next generation
sequence analysis done in 15 primary bladder adenocarcinomas,
in whichmutations were found inCTNNB1 (encoding β-catenin)
(3/15, 20%), including activating missense mutations at known
hotspots (p.D32N and p.S45F) and amplification; in the study,
the immunohistochemistry analysis revealed β-catenin nuclear
localization in mutated samples. In addition to these findings,
the COSMIC database lists 10/29 mutations (all missense)
around Ser33, Ser41, and adjacent residues, from 764 samples of
transitional cell carcinoma of the bladder evaluated. The list is
shown in Supplementary Table 4.
Expression Analysis of Ephrin-B1 and
Related Proteins in MB49 and MB49-I Cells
Studies have identified Ephrin-B1 as a target gene of β-catenin
nuclear transcriptional activity (57–59). Moreover, Ephrin-
B1 expression has been associated to tumor progression and
invasion in cell models (60, 61) and in different cancer types
[hepatocarcinoma: (62), ovarian: (63), gastric: (64)]. Other
members of the Ephrin family have been studied in BC. Among
them, a higher expression of Ephrin-A1 and EphA2 receptor
was found in BC cell lines and in advancing tumor compared to
controls, as well as an association between their expression and
tumor stage (65). Moreover, a high expression of arterial Ephrin-
B2 and venous EphB4 receptor was reported in BC, and proposed
to contribute to tumor angiogenesis (66).
Based on this background information, Ephrin-B1
mRNA and protein levels were determined in both cell
lines, finding significantly higher expression of Ephrin-B1
transcript in MB49-I cells than in MB49 cells (Figure 4A). In
agreement with these results, a stronger signal for Ephrin-B1
was found in MB49-I than in MB49 protein cell extracts
(Figure 4B). This increase was also evidenced by fluorescence
immunocytochemistry, with an Ephrin-B1 signal >300%
higher in MB49-I cells than in MB49 cells (Figure 4C). To
evaluate the association between Ephrin-B1 expression and
an invasive cellular behavior, MB49-I cells were transfected
with Ephrin-B1 (MB49I-siRNAEphrin-B1 cells) or scramble
(MB49I-siRNAControl) siRNA. The effectiveness of the
procedure was confirmed by a decrease in Ephrin-B1 mRNA
levels (Figure 4D). MB49-I siRNA Ephrin-B1 treated cells
depicted lower migratory and invasive capacity than control
cells (Figures 4E,F).
Co-expression of Ephrin-B1 and the EphB2 receptor has
been observed in small cell lung cancer (67), gastric cancer
(64) as well as in medulloblastoma (61). Also, their co-
expression was related to metastasis by immunohistochemistry
in a study done in 50 cholangiocarcinoma samples (68).
Based on these findings, EphB2 expression was evaluated
in total protein cell extracts, finding 3 times higher levels
in MB49-I cells than in MB49 cells (Figure 4G). These
findings are in agreement with the association reported
between high EphB2 expression and EMT induction and
progression of human cervical cancer (69), although they
contrast with a report describing its decrease in human BC
samples (70).
Among several signal transduction mechanisms, Ephrin-
B1 interaction with EphB2 receptor results in its activation,
which is followed by Stat3 recruitment, phosphorylation and
enhanced transcriptional activation (71). Deregulation of Stat3
signaling has been reported in several solid tumors, among
them BC (72), and its activation has been associated to
tumor invasion and metastasis (73). Thus, the expression of
Stat3 and the Tyr705-phospho Stat3 (pStat3) activated form
was analyzed in both cell lines, finding a 35% increase in
pStat3/Stat3 ratio in MB49-I cells (Figure 4H). Moreover, the
expression of Stat3 target genes, specifically Urokinase-type
Plasminogen Activator (uPA) and its receptor uPAR (Urokinase-
type Plasminogen Activator Receptor) was evaluated, finding
higher levels of both transcripts in MB49-I cells compared to
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MB49 cells (Figure 4I). In line with these findings, uPA activity
was previously reported in MB49-I cells conditioned media (11).
These molecules play a fundamental role in tissue remodeling
during invasion and metastasis, and their expression was related
to BC poor prognosis (74). uPA and uPAR expression has
been related to β-catenin transcriptional activity in colorectal
tumors (75).
Expression Analysis of E-cadherin,
β-catenin, and Ephrin-B1 in Murine and
Human Bladder Tumors
Taking into account findings obtained in cell cultures of the BC
murine model, orthotopic tumors were derived from both cell
lines, and immunodetection of E-cadherin, β-catenin, pSer33-
β-catenin, and Ephrin-B1 was done in paraffin-embedded tissue
FIGURE 5 | Immunohistochemical analysis of E-cadherin, β-catenin and pSer33-β-catenin in murine and human bladder tissues. (A) Colorimetric
immunohistochemistry of: Top: E-cadherin (610181; 2µg/ml), Middle: β-catenin (610153; 2µg/ml) and pSer33-β-catenin (Ser33-R; 2µg/ml) in paraffin sections of
normal bladder (left), MB49 tumors (middle), and MB49-I tumors (right). Bar = 20µm (Magnification 40×). Contrast staining was performed using hematoxylin.
(B) Colorimetric immunohistochemistry of E-cadherin (HECD-1; 0.6µg/ml), β-catenin (610153; 2µg/ml), and pSer33-β-catenin (Ser33-R; 2µg/ml) in paraffin sections
of bladder tissue from patients with superficial or infiltrating BC. In addition, a non-tumor section of bladder from patients with infiltrating BC after cystectomy is
included. Bar = 20µm (Magnification 40×). Contrast staining was performed using hematoxylin.
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sections; for all proteins evaluated, murine bladder C57BL/6mice
bladders were included as controls (non-tumor). E-cadherin
was immunolocalized at the cell membrane and cytoplasm in
normal bladder; contrasting, a cytoplasm signal was mainly
found in MB49 tumors, and a low intensity or undetectable
signal in MB49-I tumors (Figure 5A, top). β-catenin was
FIGURE 6 | Immunohistochemical analysis of Ephrin-B1 in murine and human bladder tissues. (A) Colorimetric immunohistochemistry of Ephrin-B1 (A-20; 2µg/ml) in
paraffin sections of normal bladder (left), MB49 tumors (middle), and MB49-I tumors (right). Bar = 20µm (Magnification 40×). Contrast staining was performed using
hematoxylin. (B) Colorimetric immunohistochemistry of Ephrin-B1 (A-20; 2µg/ml) in paraffin sections of bladder tissue from patients with superficial or infiltrating BC.
In addition, a non-tumor section corresponding to bladder of a patient diagnosed with infiltrating BC and undergoing cystectomy is included. Bar = 20µm
(Magnification 40×). Contrast staining was performed using hematoxylin. (C) Analysis of the relationship between Ephrin-B1 expression and different
clinico-pathological parameters in a set of BC samples. Ephrin-B1 staining analysis was performed assigning a score according to the percentage of stained cells (0,
no stained cells, 1:1–29%, 2:30–69%, 3:70–100%) and the intensity of the signal (0, no staining; 1: weak; 2: moderate; 3: strong). The total score was calculated after
adding both scores. The P-value was calculated using Pearson’s Chi square test. *P < 0.05.
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immunolocalized at the cell membrane and cytoplasm of normal
bladders and MB49 tumors, while MB49-I tumors showed a
signal in the nucleus in a high proportion of cells (Figure 5A,
middle). Moreover, pSer33-β-catenin immunodetection revealed
a strong signal in both normal bladder and MB49 tumors,
but very weak in MB49-I tumors (Figure 5A, bottom). In all
cases, protein subcellular localization and signal intensity was
comparable to that found in both cells growing in monolayers.
A similar analysis done in human tumor samples from
patients diagnosed with BC, revealed a strong signal for E-
cadherin in the cell membrane of sections of the tumor classified
as non-tumor tissue, and a weaker signal in the cytoplasm of
tumor sections from superficial and infiltrating tumors, with
lowest intensity in the latter (Figure 5B, top), in agreement
with previous reports in human BC (2, 19, 20). β-catenin was
immunodetected at the cell membrane of non-tumor bladder
and superficial tumors, but alterations in its expression and
localization were observed as previously reported (19, 20). In
particular, a cytoplasmic and nuclear signal was found in a
subset of infiltrating tumors evaluated (Figure 5B, middle).
This localization of β-catenin was similar to that reported
in 87% (26/30) of MIBC evaluated, which was associated it
with poor prognostic parameters, among them tumor grade,
stage, microvessel density, vascular invasion, and lymph node
metastasis (53). For pSer33-β-catenin, a cytoplasmic staining
was observed in non-tumoral bladder and superficial tumors,
although with less intensity, while no signal was detected in
infiltrating tumors (Figure 5B, bottom).
Regarding Ephrin-B1 immunodetection, MB49-I tumors
depicted a stronger signal compared to normal bladders and
MB49 tumors (Figure 6A). To assess Ephrin-B1 expression in
human BC, two studies were done. First, fresh biopsies of tumor
and non-tumor mucosa were obtained from 10 patients during
radical cystectomy. Transcript expression assessed by real-time
PCR revealed higher (P < 0.05) Ephrin-B1 levels in tumor
vs. non-tumor samples (Non tumor = 0.001446 ± 0.0006982,
Tumor= 0.003612± 0.001740).
Ephrin-B1 immunohistochemical analysis was done in
superficial and infiltrating tumors; normal bladder tissue sections
found in tumor pieces were also evaluated. A faint or absent
signal was observed in the urothelium of the non-tumoral
section, while a signal was detected in all tumors (Figure 6B).
A low or high Ephrin-B1 score was assigned, according to the
percentage of stained cells and the signal intensity. As result, a
positive association (P = 0.031) was found between Ephrin-B1
expression and tumor stage (Figure 6C), with a high proportion
of infiltrating tumors (15/18, 83.4%) depicting a high score. Half
of superficial tumors (10/20; 50%) showed a weak signal for
Ephrin-B1, but 10 superficial tumors depicted a strong signal,
6 of which were high grade, and other 2 were large tumors
with multifocal sites. A positive association was also found
between Ephrin-B1 expression and tumor grade (P= 0.005), with
79% high-grade tumors depicting a high score. Likewise, 70%
low-grade tumors had a low score. No significant relationship
was found between Ephrin-B1 staining and the occurrence
of metastasis.
E-cadherin expression was also analyzed in the 38 samples,
and compared with Ephrin-B1 results, finding 74% tumors
depicting an abnormal E-cadherin expression and high Ephrin-
B1 expression, although no significant relationship was found
between both proteins (Figure 6C). No significant relationship
was also found between E-cadherin signal and tumor stage, grade,
or metastasis (Supplementary Table 5).
Altogether, findings reported in this investigation further
characterized changes in E-cadherin and EMT-related molecules
in BC. Using a combination of bioinformatics, a murine
model of tumor aggressiveness and BC patient samples, the
expression of Ephrin-B1 and related proteins is reported for
the first time in association to BC progression/aggressiveness,
gaining knowledge on the underlying mechanisms of BC.
Evaluation of Ephrin-B1 in a multicenter study with a large
cohort of patients will help confirming its role as a biomarker
of BC aggressiveness. Since antibodies, recombinant proteins,
and peptides developed to target the Ephrin/Eph ligand-
receptor system have been reported to reduce tumor growth
in breast, prostate, colon, head, and neck cancer animal
models and some molecules are under investigation in clinical
trials (76), additional studies with these molecules in BC will
contribute to determine Ephrin-B1 role as therapeutic target of
disease progression.
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